Loading the records…
Loading the records…
HR 7902 (Safeguarding Women from Chemical Abortion Act) would withdraw FDA approval for mifepristone for pregnancy termination and create a federal tort for harm from chemical abortion drugs. The bill was introduced March 12, 2026, referred to two committees, and is in early legislative stages with only 6 cosponsors. Revenue exposure for $PFE and $TEVA is immaterial to their overall financials — less than 0.1% of revenue for each. The bill has effectively no near-term market impact.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
This bill has negligible market implications. $PFE at $26.71 (near 52-week low of $21.97) faces headwinds from LoE on Xeljanz, Ibrance, and Eliquis patent cliffs — not from a low-revenue product like mifepristone. $TEVA at $35.26 (near 52-week high of $37.35) is rallying on positive pipeline news and AJOVY/COPAXONE generic defense. Traders should not factor HR 7902 into positions on either stock. The only scenario that would change the market calculus is a surprise markup or hearing scheduling that signals bill progression — currently no evidence of that.
HR 7902 was introduced in the House on March 12, 2026 by Representative Harshbarger (R-TN) with 6 cosponsors. It has been referred to the Committee on Energy and Commerce and the Committee on the Judiciary. A companion bill (S4066) has been introduced in the Senate and referred to HELP Committee. The bill is in very early legislative stages — neither committee has held hearings or marked up the bill. Passage probability in the 119th Congress is low given the limited cosponsor support, divided government context, and the fact that similar bills have not advanced in prior sessions.
The bill operates through two mechanisms: (1) deeming the FDA-approved application for mifepristone for pregnancy termination withdrawn after 14 days of enactment, making introduction into interstate commerce a violation of the FD&C Act; (2) establishing a federal tort cause of action for women harmed by chemical abortion drugs. The bill does not authorize or appropriate any federal spending — funding_amount_usd is $0.
Structural winners and losers: There are no material winners from this bill. The only identified losers are $PFE and $TEVA, which manufacture branded and generic mifepristone respectively. However, the US mifepristone market for pregnancy termination (the relevant portion) is estimated at approximately $30-50M annually — a rounding error for Pfizer's $58B+ and Teva's $16B in annual revenue. Neither company has meaningful dependence on this product line.
Real market data analysis: $PFE is trading at $26.71, down -1.11% over 7 days and -4.91% over 30 days. The stock has been declining from $27.56 on April 17 to $26.70 on April 30. This decline is attributable to broader pharma sector trends (patent cliff concerns, pipeline readouts) — not to this bill. $TEVA is trading at $35.26, up +15.08% over 7 days and +17.07% over 30 days, driven by positive late-stage trial data for olanzapine LAI and generic launch timelines — not related to mifepristone legislation.
Remaining legislative path: The bill must pass through two House committees (Energy & Commerce; Judiciary) before a floor vote, then clear the Senate (where companion S4066 faces similar hurdles), then be signed by the President. No hearings are scheduled. Given the early stage and limited momentum, realistic timeline for any movement would be late 2026 at the earliest, if at all.
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →